This opportunity is now closed.

Funded PhD Opportunity

Senolytic compounds as new medicines for chronic diseases of ageing.

Subject: Biomedical Sciences


Summary

Ageing is thought be a normal physiological process, however ageing is the single biggest risk factor for variety of chronic diseases. Little is known about the molecular processes that can be targeted to delay ageing. One such process is cellular senescence. Senescent cells irreversibly stop dividing and enter a state of permanent growth arrest.  As we age, the capability of the immune system to target and eliminate senescent cells is decreased and we start to accumulate these in our body. Escape from senescence is carcinogenic, hence senescence serves a vital tumour suppressive function.

These accumulating senescent cells in our bodies secrete a variety of chemical signals that can cause progressive organ dysfunction. Hence, targeting senescence in older individuals maybe vital to treat chronic diseases of ageing. Compounds that remove such cells in organisms are called senolytics. One disease area that we hope to target using senolytics is Atrial Fibrillation (AF). AF is the most common disturbance of heart rhythm in all adult age groups. To control symptoms from AF many patients receive medications to control the heart rate and/or the rhythm. The majority of these anti-arrhythmic treatments target symptoms and can have serious side effects. Hence, development of new and innovative medicines such as senolytics is needed urgently.

Our hypothesis is that targeted elimination of senescenct cells in heart can cure AF. We will target senescence using various small molecue drugs and novel natural compounds including a panel of  >1,000 FDA approved drugs in the LINCS database for  repurposing screen. We have developed and tested special bioinformatics algorithms in the framework of gene expression connectivity mapping and successfully applied this advanced technique to repurpose drugs for a number human diseases including cancers [Wen et al 2017, Oncotarget] and cystic fibrosis [Malcomson B, et al. 2016 PNAS].

Recently, there has been an exponential increase in publication of omics datasets (including many by Dr Rai) specific to senescence. Using machine learning and artificial intelligence these datasets will be mined for pathways and drug combinations that can “push” senescent cells to apoptosis. The bioinformatic discovery will be complemented by in vitro studies as follows.

Firstly we will use our ER Ras senescence model system. ER Ras is an inducible senescence model, where we have engineered HRasG12V oncogene into IMR90 cells and these can be made senescent just by adding tamoxifen.

Second model system to be utilized will the etoposide induced DNA damage model of senescence. Here, we will treat atrial specific cardiomyocytes with 50 uM of etoposide for 24 hours to induce senescence. For a compound to be senolytic, it would have to kill senescent cells in both models as opposed to proliferating control cells. We believe this could lead to discovery of innovative treatment modalities for AF.

The proposed 3-year project will be based at the Centre for Personalized Medicine (CPM) under the supervision of Dr Rai, Dr McGilligan, Dr Zhang, research lecturers and alongside Professor Bjourson, centre director. The project will also involve active collaboration with Professor Peace, Consultant Cardiologist at Altnagelvin Hospital.


Essential criteria

  • Upper Second Class Honours (2:1) Degree or equivalent from a UK institution (or overseas award deemed to be equivalent via UK NARIC)
  • Sound understanding of subject area as evidenced by a comprehensive research proposal

Desirable Criteria

If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.

  • First Class Honours (1st) Degree
  • Masters at 65%
  • Research project completion within taught Masters degree or MRES
  • Practice-based research experience and/or dissemination
  • Experience using research methods or other approaches relevant to the subject domain
  • Work experience relevant to the proposed project
  • Publications - peer-reviewed
  • Experience of presentation of research findings
  • A comprehensive and articulate personal statement
  • Relevant professional qualification and/or a Degree in a Health or Health related area

Funding

    Vice Chancellors Research Scholarships (VCRS)

    The scholarships will cover tuition fees and a maintenance award of £14,777 per annum for three years (subject to satisfactory academic performance). Applications are invited from UK, European Union and overseas students.

    DFE

    The scholarship will cover tuition fees at the Home rate and a maintenance allowance of £ 14,777 per annum for three years. EU applicants will only be eligible for the fees component of the studentship (no maintenance award is provided).  For Non EU nationals the candidate must be "settled" in the UK.


Other information


The Doctoral College at Ulster University


Reviews

My experience has been great and the people that I have worked with have been amazing

Kieran O'Donnell - 3D printing of biological cells for tissue engineering applications

Watch Video  

Completing the MRes provided me with a lot of different skills, particularly in research methods and lab skills.

Michelle Clements Clements - MRes - Life and Health Sciences

Watch Video  

Throughout my PhD I’ve been provided with continuous support and guidance by my supervisors and the staff at the University.I’ve also received many opportunities to further enhance my professional development in the form of teaching experience and presenting my work at conferences which will aid in my pursuit of a career in academia or industry.

William Crowe


Key dates

Submission deadline
Monday 18 February 2019

Interview Date
w/c 11, 18 and 25th March 2019


Campus

Magee campus

Magee campus
A key player in the economy of the north west


Contact supervisor

Dr Taranjit Singh Rai


Other supervisors


Applying

Apply Online

Related Funded Opportunities in: Biomedical Sciences ,

The production of rhamnolipid biosurfactant by Pseudomonas aeruginosa growing in biofilms.

Closing date:
Sunday 1 September 2019
Subject:
Biomedical Sciences

 View Details

The regulation of rhamnolipid biosynthesis in Burkholderia thailandensis.

Closing date:
Sunday 1 September 2019
Subject:
Biomedical Sciences

 View Details

Diabetes

Subject:
Biomedical Sciences

 View Details

Genomic Medicine

Subject:
Biomedical Sciences

 View Details

Stratified Medicine

Subject:
Biomedical Sciences

 View Details

Using the Eye to Predict risk for Cardiovascular disease- The Living Lab

Closing date:
Friday 27 September 2019
Subject:
Biomedical Sciences|Engineering

 View Details

Novel amphibian skin peptide-analogues for the treatment of type-2 diabetes

Closing date:
Wednesday 18 September 2019
Subject:
Biomedical Sciences

 View Details

The design and analysis of a novel photo-activated antimicrobial system

Closing date:
Sunday 1 September 2019
Subject:
Biomedical Sciences

 View Details

Optometry and Vision Science

Subject:
Biomedical Sciences

 View Details

MRes in Biomedical Sciences

Subject:
Biomedical Sciences

 View Details

Molecular Pathology of Glaucoma

Closing date:
Wednesday 1 January 2020
Subject:
Biomedical Sciences

 View Details